One Biosciences Secures Major Funding
One Biosciences, a company focused on precision oncology technology, recently announced it has raised €15 million in Series A funding. This round of financing, led by Redmile Group and Blast, has attracted investments from several notable entities including Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures. With this latest funding, the total capital raised by One Biosciences exceeds €20 million.
The primary goal of this financing is to further develop OneMap™, an innovative artificial intelligence-driven single-cell transcriptomic platform. This platform aims to unlock insights from individual tumor profiles that can help clinicians make better-informed treatment decisions and optimize clinical trials.
Strengthening Clinical Applications
Hedi Ben Brahim, CEO of One Biosciences, expressed enthusiasm about the funding, stating, "This investment will allow us to translate our breakthrough single-cell technology into real-time insights that directly aid physician decisions and improve patient outcomes." This capital will not only support clinical advancements but also help expand strategic partnerships with pharmaceutical and biotechnology firms, which are critical to One Biosciences’ mission to improve cancer care.
OneMap™ has the potential to play a significant role in patient selection, therapy development, and optimizing clinical trials. By mapping out the heterogeneity of tumors at the single-cell level, the technology could lead to more personalized and effective treatment approaches. The funds raised will also assist in training their AI algorithms using proprietary datasets from single-cell samples, enhancing the platform's predictive abilities concerning responses to various types of cancer therapies.
Industry Experts Weigh In
Dr. Céline Vallot, co-founder of One Biosciences and a leading researcher at the Curie Institute, noted that this investment aligns with the company's capacity to leverage proprietary datasets to train their AI algorithms effectively. This development could substantiate their predictive capabilities regarding oncology therapeutics from clinical samples.
Moreover, Dr. Mehdi Touat, an assistant professor at Assistance Publique - Hôpitaux de Paris, highlighted that while the use of next-generation sequencing has advanced cancer care, its benefits are largely limited to a small subset of patients. He emphasized that clinically validated single-cell profiling could be a game-changer in both diagnostics and therapeutic strategies for oncology.
About One Biosciences
Founded in 2020 by Dr. Céline Vallot and the Home Biosciences team, One Biosciences is at the forefront of AI-driven oncology solutions, pioneering clinical-grade single-cell tumor transcriptomic profiling. The organization collaborates with several esteemed institutions, including the Curie Institute, Gustave Roussy Institute, and the Assistance Publique - Hôpitaux de Paris. Additionally, the firm has received support from significant entities such as Medicen, PSCC, and Matwin.
The company aims to empower clinicians with tools that enable them to choose the most suitable treatments for their patients by decoding tumor diversity through standard clinical samples. This initiative not only stands to improve individual patient care but significantly enhances the efficacy of clinical trials, ultimately driving progress in the fight against cancer.
For further details, please visit
One Biosciences.